Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-558,197
Closed -$50.7M 3637
2024
Q4
$50.7M Buy
558,197
+553,435
+11,622% +$50.8M 0.11% 200
2024
Q3
$460K Sell
4,762
-122
-2% -$11.9K ﹤0.01% 1662
2024
Q2
$448K Buy
4,884
+22
+0.5% +$2.04K ﹤0.01% 1614
2024
Q1
$448K Sell
4,862
-42
-0.9% -$3.94K ﹤0.01% 1583
2023
Q4
$466K Buy
4,904
+2,174
+80% +$203K ﹤0.01% 1547
2023
Q3
$255K Sell
2,730
-3,070
-53% -$284K ﹤0.01% 1401
2023
Q2
$530K Buy
5,800
+4,470
+336% +$367K ﹤0.01% 1452
2023
Q1
$97.8K Sell
1,330
-4,884
-79% -$423K ﹤0.01% 1601
2022
Q4
$519K Buy
6,214
+4,306
+226% +$388K ﹤0.01% 1224
2022
Q3
$185K Buy
+1,908
New +$228K ﹤0.01% 1671
2022
Q2
Sell
-1,368
Closed -$236K 2380
2022
Q1
$236K Sell
1,368
-2,057
-60% -$307K ﹤0.01% 2071
2021
Q4
$554K Sell
3,425
-1,324
-28% -$213K 0.01% 1513
2021
Q3
$708K Buy
4,749
+1,095
+30% +$228K 0.01% 1001
2021
Q2
$895K Sell
3,654
-25
-0.7% -$6.56K 0.01% 899
2021
Q1
$974K Sell
3,679
-114
-3% -$32.2K 0.02% 787
2020
Q4
$1.11M Sell
3,793
-4,024
-51% -$1.03M 0.02% 654
2020
Q3
$1.85M Buy
+7,817
New +$1.78M 0.04% 435
2020
Q1
Sell
-10,958
Closed -$1.83M 678
2019
Q4
$1.83M Sell
10,958
-714
-6% -$106K 0.08% 297
2019
Q3
$1.53M Sell
11,672
-40
-0.3% -$5.21K 0.03% 633
2019
Q2
$1.42M Buy
+11,712
New +$1.39M 0.03% 659

Other funds holding AMED

Pacer Advisors's AMED Position: Q1 2025 in Review

Pacer Advisors sold out of Amedisys (AMED) in Q1 2025, closing a stake of 558,197 shares — an estimated $50.7M sold.

Pacer Advisors first reported a position in AMED in Q2 2019 and held it in 20 quarters. The position peaked at $50.7M in Q4 2024. 304 funds tracked by Wall St. Rank hold AMED as of Q1 2025.

  • Pacer Advisors reported no remaining Amedisys position as of Q1 2025 after selling out during the quarter.
  • Pacer Advisors sold 558,197 Amedisys shares in Q1 2025, an estimated $50.7M.
  • Pacer Advisors first reported a position in Amedisys in Q2 2019 and held it in 20 quarters.
  • Pacer Advisors's Amedisys position peaked at $50.7M in Q4 2024.
  • 304 funds tracked by Wall St. Rank held Amedisys as of Q1 2025.

Based on Pacer Advisors's 13F filing for Q1 2025, filed 6 May 2025.